Intravitreal injection (IVI) of antivascular endothelial growth factors and dexamethasone implants are among the most performed procedures in ophthalmology, as they are used to treat various retinal diseases. Although considered safe, some rare but sight-threatening complications can occur, like endophthalmitis and retinal detachment. Here, we report a case of a 53-year-old male with a history of lymphoma (treated with chemotherapy in 2016 and currently on Cellcept and low-dose oral prednisolone), diabetes mellitus (DM), hypertension (HTN), and hyperlipidemia, who presented shortly after intravitreal Ozurdex injection in the left eye with retinal detachment (RD). Ozurdex is a valuable option for treatment of chronic diabetic macular edema (DME). This case highlights the need for a high index of suspicion for retinal detachment in pseudophakic patients with compromised retina, even after seemingly routine Ozurdex injection.
Alkhamees et al. (2026) studied this question.